News & Events

Back Home
Previous | NextPages2 3 4 5 6 7 8  Next >> [31]
  • January 17, 2012

    Barry Grossman gave a presentation on the requirements and methodologies used to Go Private and participated on a panel discussing Privatization of Chinese Companies.

    Click here to view the presentation

  • January 11, 2012

    Ellenoff Grossman & Schole LLP was ranked #4 for issuer representation in IPO transactions  (by number of transactions) for 2011.

    Click here to view the rankings

  • January 4, 2012

    Ellenoff Grossman & Schole LLP was ranked #1 for placement agent representation in PIPE transactions (by number of transactions) for 2011.

    Click here to view the rankings

  • December 30, 2011

    AspenBio Pharma, Inc. announced the closing of their registered direct offering in the amount of $1,637,100.  EG&S acted as counsel to the Placement Agent.
     

  • December 28, 2011

    Oculus Innovative Sciences, Inc. announced the closing of their registered direct offering in the amount of $2,081,100.  EG&S acted as counsel to the Placement Agent.
     

  • December 28, 2011

    Quadrant 4 Systems Corporation announced the closing of their private placement in the amount of $800,000.  EG&S acted as counsel to the Investor.
     

  • December 27, 2011

    Catasys, Inc. announced the closing of their registered direct offering in the amount of $974,999. EG&S acted as counsel to the Placement Agent.
     

  • December 21, 2011

    StemCells, Inc. announced the closing of their underwritten public offering in the amount of $10,000,000. EG&S acted as counsel to the Underwriter.
     

  • December 13, 2011

    PhotoMedex, Inc., a NASDAQ listed company, and Radiancy, Inc., a private Delaware company,  announced the completion of their merger.  Pursuant to the merger, the former stockholders of Radiancy received shares of Photomedex valued on the date of closing at approximately $235 million and collectively own approximately 75% of PhotoMedex, Inc. following the merger. Radiancy became a majority-owned subsidiary of PhotoMedex. EG&S acted as counsel to Radiancy.

  • December 13, 2011

    Cell Therapeutics Inc. announced the closing of their registered direct in the amount of $20,000,000. EG&S acted as counsel to the Placement Agent.

Previous | NextPages2 3 4 5 6 7 8  Next >> [31]